Fount Bio Awarded Prestigious Innovation of the Year at 2024 IMCAS
Fount Bio wins first prize at the Innovation Tank competition for its development of the world’s first platform of products that build crosslinked hyaluronic acid within living tissues
CAMBRIDGE, MA February 12, 2024 – Life sciences innovator Fount Bio, Inc., won first place in the Innovation Tank event at the IMCAS World Congress 2024 in Paris. In this highly competitive and coveted event, Fount Bio was invited to present its Flī-Derm™ aesthetic dermatology product on February 2, winning the Innovation of the Year award.
IMCAS is the world’s largest conference dedicated to aesthetic medicine and aging science. This year’s event was attended by 18,000 participants from around the world including innovators, physicians, and representatives from industry and finance. The Innovation Tank competition, which was styled after the Shark Tank television show, allowed select participants to present their innovations, followed by a question-and-answer period by a 10-member jury of senior opinion leaders from medicine, industry, and finance.
Based on Fount Bio’s proprietary Flī-HA™ bioorthogonal chemistry platform, the Flī-Derm™ product enables the building of durable forms of hyaluronic acid (HA) within the dermis via a liquid formulation that is delivered with a gentle form of assisted delivery. In a blinded clinical study, Flī-Derm™ was shown to significantly reduce fine lines and wrinkles relative to control treatment, while demonstrating exceptional safety and tolerability.
“We are thrilled to be recognized as the Innovation of the Year by IMCAS’ Innovation Tank. This is strong validation of the exciting potential of our Flī-Derm™ product and the power of our Fli-HA™ technology platform,” said Fount Bio co-founder and CEO Doug Levinson, Ph.D. “We look forward to advancing our product towards commercial launch and providing the medical aesthetics community with exciting new possibilities for improving the health and well-being of patients.”
Fount Bio’s Flī-HA technology platform represents a novel approach to overcome key challenges associated with delivery of large glycopolymers like HA, allowing tailored placement onto tissue surfaces or within tissues where they are retained for extended periods of time. In addition to Flī-Derm™, Fount Bio has a pipeline of medical products in development for ophthalmology and women’s health.
About Fount Bio
Fount Bio is a life science company developing a pipeline of innovative products for medical applications based on proprietary technology that combines innovations in biorthogonal chemistry and glycopolymer science. Led by an experienced management team and highly respected scientific advisors, Fount Bio combines scientific excellence, a pioneering spirit, and extensive experience in building high-value life sciences companies. The company is headquartered in Cambridge, Massachusetts, USA. Learn more at fountbio.com
Please direct press inquiries to info@fountbio.com or +1 (617) 249-3552
